Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Can Capecitabine be used Instead of Concurrent Bolus 5-FU in Postoperative Chemoradiotherapy for Gastric Adenocarcinoma?

  • Yoney, Adnan (Karadeniz Technical University, Faculty of Medicine, Department of Radiation Oncology) ;
  • Isikli, Levent (Okmeydani Training and Research Hospital, Department of Radiation Oncology)
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: 5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma. However, FU is not well tolerated in a significant proportion of patients. Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases. We compared the toxicity, local and distant control and survival rates with FU or oral CA during the course of concurrent radiotherapy to assess the role of CA used instead of FU. Materials and Methods: We conducted an analysis of survival, disease control and toxicity data in 46 patients treated with postoperative chemoradiation following total or subtotal gastrectomy for gastric adenocarcinoma with either FU or CA between January 2008 and December 2012. Results: Median follow-up was 19 months (range: 3-59), median survival time was 23 ({\pm}6.08) months and 1-3 years overall survival (OS) rates were 64.9-39% for all patients. Compared with the CA regimen, the incidence of treatment interruption was higher with FU (p=0.023), but no significant differences were seen in local control (p=0.510), distant recurrences (p=0.721) and survival rates (p=0.866) among patients. Conclusions: Concurrent CA with radiotherapy seems to be a more tolerable and an equally effective regimen for the postoperative treatment of gastric adenocarcinoma when compared to FU.

Keywords

References

  1. Dahan L, Atlan D, Bouche O, et al (2005). Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients. Gastroenterol Clin Biol, 29, 11-15. https://doi.org/10.1016/S0399-8320(05)80688-8
  2. Fiorica F, Cartei F, Enea M, et al (2007). The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. Cancer Treat Rev, 33, 729-40. https://doi.org/10.1016/j.ctrv.2007.08.005
  3. Gunderson LL, Sosin H (1974). Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer. 34, 1278-92. https://doi.org/10.1002/1097-0142(197410)34:4<1278::AID-CNCR2820340440>3.0.CO;2-F
  4. Hundahl SA, Phillips JL, Menck HR (2000). The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 88, 921-32. https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<921::AID-CNCR24>3.0.CO;2-S
  5. Jansen EP, Boot H, Saunders MP, et al (2007). A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 69,1424-28. https://doi.org/10.1016/j.ijrobp.2007.05.004
  6. Kim S, Kim JS, Jeong HY, et al (2011). Retrospective analysis of treatment outcomes after postoperative chemoradiotherapy in advanced gastric cancer. Radiat Oncol J, 29, 252-9. https://doi.org/10.3857/roj.2011.29.4.252
  7. Kunz PL, Gubens M, Fisher GA, et al (2012). Long-term survivors of gastric cancer: A California population-based study. J Clin Oncol, 30, 3507-15. https://doi.org/10.1200/JCO.2011.35.8028
  8. Lee HS, Choi Y, Hur WJ, et al (2006). Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol, 12, 603-7. https://doi.org/10.3748/wjg.v12.i4.603
  9. Lim DH, Kim DY, Kang MK, et al (2004). Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view. Br J Cancer, 91, 11-7. https://doi.org/10.1038/sj.bjc.6601896
  10. Macdonald JS, Smalley SR, Benedetti J, et al (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345, 725-30. https://doi.org/10.1056/NEJMoa010187
  11. Marcenaro M, Foppiano F, Durzu S, Barra S, Corvo R (2006). Kidney-sparing radiotherapy by multiple-field threedimensional technique in the postoperative management of the patients with gastric cancer: comparison with standard two-field conformal technique. Tumori, 92, 34-40.
  12. Milano MT, Garofalo MC, Chmura SJ, et al (2006). Intensitymodulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol, 79, 497-503. https://doi.org/10.1259/bjr/43441736
  13. Minn AY, Hsu A, La T, et al (2010). Comparison of intensitymodulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer, 116, 3943-52. https://doi.org/10.1002/cncr.25246
  14. Ohri N, Garg MK, Aparo S, et al (2013). Who benefits from adjuvant radiation therapy for gastric cancer? A metaanalysis. Int J Radiat Oncol Biol Phys, 86, 330-5. https://doi.org/10.1016/j.ijrobp.2013.02.008
  15. Tham CK, Choo SP, Poon DY, et al (2010). Capecitabine with radiation is an effective adjuvant therapy in gastric cancer. World J Gastroenterol, 16, 3709-15. https://doi.org/10.3748/wjg.v16.i29.3709
  16. Valentini V, Cellini F, Minsky BD, et al (2009). Survival after radiotherapy ingastric cancer: Systematic review and metaanalysis. Radiother Oncol, 92, 176-83. https://doi.org/10.1016/j.radonc.2009.06.014
  17. Van Cutsem E, Twelves C, Cassidy J, et al (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol, 19, 4097-106. https://doi.org/10.1200/JCO.2001.19.21.4097
  18. Wanebo HJ, Kennedy BJ, Chmiel J, et al. (1993). Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 218, 583-92. https://doi.org/10.1097/00000658-199321850-00002

Cited by

  1. Experimental Study on Sustained-release 5-Fluorouracil Implantation in Canine Peritoneum and Para-aortic Abdominalis vol.15, pp.1, 2014, https://doi.org/10.7314/APJCP.2014.15.1.407
  2. Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer vol.15, pp.20, 2014, https://doi.org/10.7314/APJCP.2014.15.20.8661
  3. Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer vol.13, pp.1, 2015, https://doi.org/10.1186/s12957-015-0737-9
  4. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1449